Back to search

Article

COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN) Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients – results from a randomized, double-blind, placebo-controlled phase II clinical trial.

2022-08-09

Abstract excerpt

COVID-19 strongly influences our daily lives, and there is urgent need for a therapy treating early infections to prevent progression.CARVIN was a randomized, parallel, double-blind, placebo-controlled study. Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0·02% or 0·1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. Investigators...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ea70b011-a00f-5c15-bcc9-bac455f22a68
DOI
10.21203/rs.3.rs-1893502/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN) Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients – results from a randomized, double-blind, placebo-controlled phase II clinical trial.DOI 10.21203/rs.3.rs-1893502/v1
COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN). Early intervention with azelastine nasal sprays reduces viral load in SARS-CoV-2 infected patients. First report on a double-blind placebo-controlled phase II clinical trial.Semantic proximity
Hydroxychloroquine with or Without Azithromycin for Treatment of Early SARS-CoV-2 Infection Among High-Risk Outpatient Adults: A Randomized Clinical TrialSemantic proximity
The real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19Semantic proximity
A randomized, placebo-controlled trial of a nasal spray solution containing broadly potent neutralizing antibodies against SARS-CoV-2 variants in healthy volunteersSemantic proximity
Oral Azvudine (FNC) Tablets in Patients infected with SARS-CoV-2 Omicron Variant: A Retrospective Cohort StudySemantic proximity
Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trialSemantic proximity
TaffiX® nasal powder spray forms an effective barrier against infectious new variants of SARS-CoV-2 (Alpha, Beta and Delta)Semantic proximity
Effect of Antiseptic Mouthwash/Gargling Solutions on SARS-CoV-2 Viral Load: A Randomized Clinical TrialSemantic proximity
Pharmacometric assessment of the <i>in vivo</i> antiviral activity of ivermectin in early symptomatic COVID-19Semantic proximity
A mixture of essential oils from three Cretan Aromatic Plants (thyme, Greek sage and Cretan dittany, CAPeo) inhibits SASR-CoV-2 proliferation:<i>in vitro</i>evidence and a Proof-of-Concept intervention study in mild ambulatory COVID-19-positive patientsSemantic proximity
Evaluation of Slow-release Mucoadhesive Paste of” MUCODENTOL “in Oral Vestibule on Prophylaxis of Symptoms and Signs of COVID-19 Disease: A triple-blind, randomized clinical trialsSemantic proximity
Molnupiravir, an Oral Antiviral Treatment for COVID-19Semantic proximity
Select a neighboring publication to make it the new centre.